Latest Commercialisation News

ADX Energy reports a 17% production dip in Q3 2025 due to well downtime but boosts sales revenue by 23%, while advancing drilling plans and acquiring key infrastructure.

EMVision Medical Devices has successfully closed an oversubscribed Share Purchase Plan, raising $2 million and bringing total recent capital to $14 million. This funding positions the company to advance pivotal clinical trials and regulatory milestones for its innovative neurodiagnostic devices.

HITIQ Ltd has secured a landmark order for its PROTEQT™ mouthguards at the Winter Olympics and launched in the UK consumer market, while advancing global validation and raising over A$2 million in capital.

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.

Carnegie Clean Energy marked steady progress in Q3 2025, hitting key manufacturing milestones for its CETO wave energy system in Spain, securing €4 million in EU funding, and raising $2.1 million from shareholders to fuel commercialisation efforts.

Alexium International Group reported a 26% rise in Q1 FY26 sales driven by new business wins and expanded foam bedding applications, while navigating tighter funding conditions.

Micro-X Ltd has secured its largest-ever $3.3 million Rover Plus order from Malaysia’s Ministry of Health and is progressing critical Head CT imaging trials, supported by a $4.4 million government grant.

ABx Group Limited reports strong progress in rare earth extraction and clean chemical production, backed by strategic investments and a recent $3 million capital raise.

Artrya Limited has completed the second tranche of its share placement, raising $14.7 million to advance its AI-powered Salix platform for coronary artery disease detection.

Wide Open Agriculture advances its lupin protein commercialisation with a strategic China rollout, sustainability validation, and plans for a large-scale Australian facility.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.